Schizophrenia Clinical Trials in Chino, California
6 studies are recruiting for schizophrenia in Chino, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
- Stage
- Phase 4
- Ages
- 18 and older
- Site
- Neurocrine Clinical Site, Chino, California
- Locations
- 19 in total
- Run by
- Neurocrine Biosciences
-
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia
- Stage
- Phase 3
- Ages
- 18 to 65
- Site
- Local Institution - 0188, Chino, California
- Locations
- 59 in total
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.
- Stage
- Phase 3
- Ages
- 13 to 17
- Site
- Inland Psychiatric Medical Group., Chino, California
- Locations
- 38 in total
- Run by
- Bristol-Myers Squibb
-
A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively
- Stage
- Phase 3
- Ages
- 5 to 17
- Site
- Inland Psychiatric Medical Group., Chino, California
- Locations
- 91 in total
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
-
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Inland Psychiatric Medical Group (IPMG)-Chino, Chino, California
- Locations
- 55 in total
- Run by
- Bristol-Myers Squibb
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.
- Stage
- Phase 3
- Ages
- 18 to 65
- Site
- Neurocrine Clinical Site, Chino, California
- Locations
- 57 in total
- Run by
- Neurocrine Biosciences
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.